Antiangiogenic activity of aeroplysinin-1, a brominated compound isolated from a marine sponge

被引:81
作者
Rodríguez-Nieto, S
González-Iriarte, M
Carmona, R
Muñoz-Chápuli, R
Medina, MA
Quesada, AR
机构
[1] Univ Malaga, Fac Ciencias, Dept Bioquim & Biol Mol, E-29071 Malaga, Spain
[2] Univ Malaga, Fac Ciencias, Dept Biol Anim, E-29071 Malaga, Spain
关键词
angiogenesis; angiogenesis inhibitor; endothelial cells; apoptosis;
D O I
10.1096/fj.01-0427fje
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
(+)- Aeroplysinin-1, an antibacterial brominated compound produced by certain sponges, was selected during a blind high-throughput screening for new potential antiangiogenic compounds obtained from marine organisms. In a variety of experimental systems, representing the sequential events of the angiogenic process, aeroplysinin-1 treatment of endothelial cells resulted in strong inhibitory effects. Aeroplysinin-1 inhibited the growth of endothelial cells in culture and induced endothelial cell apoptosis. Capillary tube formation on Matrigel was completely abrogated by addition of aeroplysinin-1 at the low micromolar range. Aeroplysinin-1 also exhibited a clear inhibitory effect on the migration capabilities of endothelial cells. Zymographic assays showed that aeroplysinin-1 treatment produced a decrease in the concentration of matrix metalloproteinase-2 and urokinase in conditioned medium from endothelial cells. Finally, aeroplysinin-1 exhibited a dose-dependent inhibitory effect on the in vivo chorioallantoic membrane assay, showing potent apoptosis-inducing activity in the developing endothelium. The in vivo inhibition of angiogenesis by aeroplysinin-1 was confirmed by the Matrigel plug assay. Together, our data indicate that aeroplysinin-1 is a compound that interferes with key events in angiogenesis, making it a promising drug for further evaluation in the treatment of angiogenesis-related pathologies.
引用
收藏
页码:261 / +
页数:27
相关论文
共 55 条
[1]  
ALBINI A, 1987, CANCER RES, V47, P3239
[2]   ASSAYS FOR ANGIOGENESIS - A REVIEW [J].
AUERBACH, R ;
AUERBACH, W ;
POLAKOWSKI, I .
PHARMACOLOGY & THERAPEUTICS, 1991, 51 (01) :1-11
[3]  
BRAKENHIELM E, 2001, FASEB J 0608
[4]   Modulation of the proteolytic balance plasminogen activator plasminogen activator inhibitor by enhanced N-myc oncogene expression or application of genistein [J].
de Veas, RG ;
Schweigerer, L ;
Medina, MA .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (11) :1736-1740
[5]   Halofuginone: a potent inhibitor of critical steps in angiogenesis progression [J].
Elkin, M ;
Miao, HQ ;
Nagler, A ;
Aingorn, E ;
Reich, R ;
Hemo, I ;
Dou, HL ;
Pines, M ;
Vlodavsky, I .
FASEB JOURNAL, 2000, 14 (15) :2477-2485
[6]  
Fajardo I, 2000, ANTICANCER RES, V20, P1691
[7]  
Fattorusso E, 1972, J Chem Soc Perkin 1, V1, P16
[8]  
FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
[9]   ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE [J].
FOLKMAN, J .
NATURE MEDICINE, 1995, 1 (01) :27-31
[10]  
FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0